Safety of an intravenous formulation of lamotrigine

Jeannine M Conway, Angela K Birnbaum, Ilo E Leppik, Page B. Pennell, James R. White, John O. Rarick, Rory P Remmel

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Purpose Intravenous (IV) formulations are useful when treating patients where oral administration is not possible and to study certain pharmacokinetic parameters such as bioavailability. We developed a stable-labeled IV formulation of lamotrigine (LTG) for studying pharmacokinetics in epilepsy patients. Methods Stable-labeled IV LTG was given to 20 persons with epilepsy (6 men; 14 women) with a mean age of 34.8 years (SD 11.7). A 50 mg dose of LTG (stable labeled) was given intravenously and replaced 50 mg of the regular morning oral dose of LTG (unlabeled, commercially available formulation). Results No significant changes in blood pressure, heart rate, or adverse events including rash were attributed to administration of a 50-mg dose of the intravenous LTG formulation. Conclusion Our results show that LTG base that is complexed with 2-hydroxypropyl-β-cyclodextrin and stable-labeled can be given safely as a tracer replacement dose.

Original languageEnglish (US)
Pages (from-to)390-392
Number of pages3
Issue number5
StatePublished - May 2014

Bibliographical note

Funding Information:
This work was supported by NIH-NINDS P50-NS16308 , NCRR M01-RR00400 (UMN) , and NCRR M01-RR00039 .


  • Cyclodextrin
  • Epilepsy
  • Intravenous
  • Lamotrigine
  • Safety


Dive into the research topics of 'Safety of an intravenous formulation of lamotrigine'. Together they form a unique fingerprint.

Cite this